Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

Key value for chemical safety assessment

Additional information

A discussion paper on basic toxicokinetics including references for assessment of absorption, distribution, metabolism, potential for accumulation and excretion is attached. A summary is provided below.


Based on the physicochemical characters (large MW, high water solubility, and low Kow), low acute oral toxicity and high repeated oral dose NOAEL (=380 mg/kg/day) of B-TTEGME in rats, it could be presumed that oral absorption of B-TTEGME is very low. Oral absorption of B-TTEGME however is evident from the slight effects (very slight centrilobular hypertrophy) that was observed in rats when orally exposed for 28 days.

The low vapour pressure of B-TTEGME (18.7 hPa at 20°C for B-TTEGME ; 120 Pa for B-TEGME) indicates it is non-volatile at room temperature, consistent with low LogPow (-4,37 for B-TEGME; for the longer chain lengths, lower LogPow are expected). Based on this, exposure of B-TTEGME through inhalation is unlikely.

Dermal penetration of B-TTEGME is expected to be very limited based on very low acute dermal toxicity (LD50>1520 mg/kg for B-TTEGME and >2000 mg/kg for B-TEGME), no dermal irritation, or sensitisation. The rate of dermal penetration of B-TTEGME has been predicted to be very low by Dermwin version 2.0 (5.59e-003 and 6.77e-004 mg/kg-day, respectively for B-TEGME and B-TetraEGME).


Based on the physicochemical properties (low Kow and high water solubility), B-TTEGME is expected to have limited distribution and to remain only in the body water upon absorption.


Based on the high molecular weight, complete miscibility with water and very low lipohilicity (Kow), the systemically absorbed B-TTEGME is expected to eliminate from the body quite rapidly with low to no bioaccumulation.


Metabolism of B-TTEGME is expected from the increase in liver weight of the rats repeatedly orally exposed to B-TTEGME. Increase in liver weight and hypertrophy is often related to enzyme induction and metabolism of the test material in the liver.  This compound would be expected to undergo oxidative O-dealkylation to afford smaller molecular weight glycol and carboxylic acid metabolites, as has been shown for other polyglycols and glycol ethers such as diethylene glycol and dipropylene glycol methyl ether.


The systemically absorbed B-TTEGME is expected to be rapidly excreted through urine upon metabolism or through bile if remained unmetabolized or conjugated with phase II enzymes as the higher molecular weight compounds from B-TTEGME are preferably excreted through bile.